AstraZeneca, Merck strike deal to advance cancer treatments

British pharmaceutical giant AstraZeneca and US peer Merck said Thursday they had agreed a multi-billion-dollar deal to jointly develop key cancer drugs.
However, AstraZeneca shares tumbled 15 percent as investors fretted over disappointing trial results for its next-generation lung cancer treatment.
Sentiment took another heavy blow on news that Astra's first-half sales were hurt by the loss of US patent protection on two blockbuster drugs.
The Merck tie-up illustrates the growing prominence of oncology in the global pharmaceutical sector.
"The strategic collaboration is expected to further increase the number of treatment options available to patients," Merck and Astra said in their joint statement. 
Merck will pay AstraZeneca up to $8.5 billion (7.2 billion euros) under the deal struck to develop and commercialise the drugs.
Central to the agreement is "a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca's Lynparza (olaparib) for multiple cancer types", the pair said. 
Lynparza is currently approved for treatment of ovarian cancer but it is hoped that this can be stretched to help fight breast, prostate and pancreatic cancers thanks to the tie-up announced Thursday, they added.
"By bringing together the expertise of two leading oncology innovators, we will accelerate Lynparza's potential," said AstraZeneca chief executive Pascal Soriot.
"This is a truly exciting step and we are pleased to work with Merck, a company that shares our passion for science to deliver new medicines for cancer patients."
Merck chief executive Kenneth C. Frazier added: "We look forward to working with AstraZeneca to create greater value for patients and shareholders than if both companies worked independently."
Merck will pay AstraZeneca an initial $1.6 billion, $750 million for licence options and up to $6.15 billion "upon successful achievement of future regulatory and sales milestones".
- 'Huge need for treatment' -
Explaining the importance of the deal to cancer patients as well as pharmaceuticals, investment director at online stockbroker AJ Bell, Russ Mould, told AFP:
"There is a huge need for treatment and many drug firms are working hard to find them. Oncology is a big part of the rejuvenation of the fortunes of the biotech sector in the US, where a (share-price) bubble burst in 2000.
"But the stocks are back in favour now as firms look to develop treatments of their own and/or buy firms who are working on them," Mould added.
AstraZeneca meanwhile added Thursday that its revenues dived 10 percent to $10.5 billion in the six months to June 30, from a year earlier.
The performance was hit by generic competition for cholesterol drug Crestor and anti-depressant Seroquel XR in the key US market.
Astra shares plunged 15.68 percent in late morning trade to £43.11, pushing London's FTSE 100 index slightly into negative territory.
"AstraZeneca's shares slumped after it continued to feel the impact of the loss of patents on profitable drugs in the US and disappointing results for a lung cancer drug trial," analyst Mould said in a client note.
"The drop in first-half revenues and the cancer trial results proved to be a toxic combination as far as investors were concerned."
On the upside for AstraZeneca, net profit soared 58 percent to $1.01 billion on the back of steep cost-cutting in the first six months of 2017.

Source:http://www.newindianexpress.com/business/2017/jul/27/astrazeneca-merck-strike-deal-to-advance-cancer-treatments-1634349.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more